DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including Advanced Hepatocellular Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Advanced Hepatocellular Carcinoma Emerging drugs, the Advanced Hepatocellular Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Advanced Hepatocellular Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Advanced Hepatocellular Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Advanced Hepatocellular Carcinoma clinical trials studies, Advanced Hepatocellular Carcinoma NDA approvals (if any), and product development activities comprising the technology, Advanced Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Advanced Hepatocellular Carcinoma Pipeline landscape @ Advanced Hepatocellular Carcinoma Pipeline Outlook Report
Advanced Hepatocellular Carcinoma Overview
Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. Unfortunately, considerable number of patients are diagnosed at advanced stage unsuitable for surgery or local treatment with poor prognosis and a median overall survival (OS) of about 6 months. Molecular targeted therapies have demonstrated promising efficacy in the management of cancer. Advanced HCC has experienced the most relevant advancements in research in HCC lately. Advanced HCC was defined as a liver tumor not eligible for local therapies given the extent of disease or liver tumors that recurred after local therapies.
Recent Developmental Activities in the Advanced Hepatocellular Carcinoma Treatment Landscape
For further information, refer to the detailed Advanced Hepatocellular Carcinoma Drugs Launch, Advanced Hepatocellular Carcinoma Developmental Activities, and Advanced Hepatocellular Carcinoma News, click here for Advanced Hepatocellular Carcinoma Ongoing Clinical Trial Analysis
Advanced Hepatocellular Carcinoma Emerging Drugs Profile
FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 .
ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials.
Advanced Hepatocellular Carcinoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma. The companies which have their Advanced Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, CStone Pharmaceuticals.
Find out more about the Advanced Hepatocellular Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Advanced Hepatocellular Carcinoma Emerging Drugs @ Advanced Hepatocellular Carcinoma Treatment Landscape
Scope of the Advanced Hepatocellular Carcinoma Pipeline Report
Dive deep into rich insights for drugs for Advanced Hepatocellular Carcinoma Pipeline Companies and Therapies, click here @ Advanced Hepatocellular Carcinoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Advanced Hepatocellular Carcinoma Mergers and acquisitions, Advanced Hepatocellular Carcinoma Licensing Activities @ Advanced Hepatocellular Carcinoma Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/